STOCK TITAN
  1. Home
  2. Sec-filings
  3. ALB
  4. [Form 4] Albemarle Corporation Insider Trading Activity

Albemarle Insider Filing: Dean Seavers Boosts Stake to 12,021 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Albemarle Corporation (ALB) – Form 4 insider transaction filing

Director Dean Seavers reported two equity awards dated 1 July 2025:

  • 2,725 common shares granted under the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors; the award vests on 1 July 2026.
  • 37 additional shares issued as accrued dividends on a July 2024 award that vested in full on 1 July 2025.

No shares were sold and no derivative securities were transacted. Following the awards, Seavers’ total direct beneficial ownership rose to 12,021 common shares. The transactions were effected at a stated price of $0, reflecting their nature as board compensation rather than open-market purchases.

The filing is routine for annual director compensation but does increase insider equity alignment and signals continued board participation in Albemarle’s long-term incentive structure.

Positive

  • Director’s shareholding increased by 2,762 shares, lifting total direct ownership to 12,021 shares and marginally strengthening insider alignment.

Negative

  • None.

Insights

TL;DR: Routine director stock grant—raises holdings to 12,021 shares, no market purchase, limited valuation impact.

The Form 4 shows a standard non-employee director grant and dividend share issuance. Because the shares were awarded at no cost, the disclosure does not reflect a discretionary market purchase and therefore carries modest signalling value. Beneficial ownership rose by 2,762 shares, a 29% increase from the pre-grant level, modestly enhancing alignment but not materially affecting Albemarle’s share float or insider sentiment indicators.

TL;DR: Governance-driven equity grant under existing 2023 Directors Plan; neutral corporate-action impact.

The award is issued pursuant to the shareholder-approved 2023 Directors Plan, consistent with best-practice governance that links board compensation to equity performance. Vesting over a one-year horizon maintains director engagement but is standard practice. No red flags emerge, and there is no dilution beyond the plan’s pre-authorised pool. Overall governance impact is neutral.

Insider Seavers Dean
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 2,725 $0.00 --
Grant/Award Common Stock 37 $0.00 --
Holdings After Transaction: Common Stock — 11,984 shares (Direct)
Footnotes (1)
  1. Shares represent an annual installment of non-employee director stock compensation pursuant to the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors of Albemarle Corporation (the "2023 Directors Plan"). Shares to vest on July 1, 2026. Represents dividends accrued on shares underlying an award granted on July 1, 2024, that vested in full on July 1, 2025, which the Issuer elected to settle in shares of common stock under the 2023 Directors Plan.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Seavers Dean
(Last) (First) (Middle)
ALBEMARLE CORPORATION
4250 CONGRESS STREET, SUITE 900
(Street)
CHARLOTTE NC 28209
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ALBEMARLE CORP [ ALB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 A 2,725(1) A $0 11,984 D
Common Stock 07/01/2025 A 37(2) A $0 12,021 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares represent an annual installment of non-employee director stock compensation pursuant to the 2023 Stock Compensation and Deferral Election Plan for Non-Employee Directors of Albemarle Corporation (the "2023 Directors Plan"). Shares to vest on July 1, 2026.
2. Represents dividends accrued on shares underlying an award granted on July 1, 2024, that vested in full on July 1, 2025, which the Issuer elected to settle in shares of common stock under the 2023 Directors Plan.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Rebekah Richards, Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Albemarle (ALB) shares did Director Dean Seavers acquire on 1 July 2025?

He received 2,725 common shares as part of his annual director compensation.

What additional shares were reported in the Form 4?

An extra 37 shares were issued as dividends accrued on a prior award vested on 1 July 2025.

Did the insider sell any Albemarle shares in this filing?

No, the filing shows only acquisitions; no shares were sold or disposed of.

What is Dean Seavers’ total direct beneficial ownership after the transactions?

His direct holdings increased to 12,021 Albemarle common shares.

When will the newly granted 2,725 shares vest?

The shares are scheduled to vest on 1 July 2026.